Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
One example: "Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Solution is here: Some appendicitis cases may not require 'emergency' surgery
Explanation: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.

Now, solve this: They said drugs that blocked the enzyme glycogen synthase kinase, or GSK3, helped mice with mixed-lineage leukemia, or MLL, live far longer than untreated mice. The finding is a surprise because prior studies have found GSK3 helped suppress unchecked cell growth in other cancers. "GSK3 has never been implicated in promoting cancer," said Dr. Michael Cleary of Stanford University in California, whose research appears in the journal Nature. Cleary's team found that blocking GSK3 fights leukemias caused by mutations in the MLL gene, which accounts for 5 percent to 10 percent of child and adult leukemias and more than three-quarters of leukemias diagnosed in infants. Cleary said only a few hundred people in the United States get MLL each year, but when babies get leukemia, they tend to get this form, although it is not clear why. While most leukemias get their start in either lymph nodes or bone marrow, MLL cancer cells can originate from both. "These patients don't typically respond well to chemotherapy. There is a real need for better treatments," Cleary said in a telephone interview. His team first got a hint that blocking GSK3 might fight MLL through routine screening tests in the lab. The researchers gave the mice with MLL lithium, a drug used to treat bipolar disease in humans. "It is not the best GSK3 inhibitor, but it is one that could be administered long-term in mice," Cleary said. Mice treated with the lithium lived significantly longer than the untreated mice. Cleary's team also used a different GSK3 inhibitor in MLL cells and found it stopped them from growing. "I think where we need to go in the future is to come up with better inhibitors that can be administered long-term," Cleary said. That may come through research of the drug in other diseases. Cleary said drug companies are developing GSK3 inhibitors as treatments for diabetes and Alzheimer's disease.
Solution:
Blocking enzyme could help in rare blood cancer.